Abstract
Transcatheter implantation of aortic valves (TAVR) has revolutionized management of severe aortic stenosis. Specific complications have been seen with 1st generation valves. Details of such were sought from the US Food and Drug Administration (FDA) MAUDE database which houses medical device reports
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have